PSG
16.3.2021 09:10:12 CET | Business Wire | Press release
Imaweb, a leading independent developer and provider of automotive and dealership digital software solutions in Europe, today announced the acquisition of Stampyt, a leading French provider of remarketing software and other digital solutions for the second-hand vehicle market. Imaweb is backed by funds advised by PSG, a leading growth equity firm that focuses on partnering with middle-market software and technology-enabled service companies.
Founded in 2015, Stampyt’s AI-driven imaging technology enables dealerships and original equipment manufacturers (OEMs) to boost their second-hand vehicle sales by providing them with innovative digital solutions to support aftersales and remarketing activities. In addition to photo and video technology, Stampyt also develops and commercialises a suite of complementary solutions allowing dealers and OEMs to, among others, inspect vehicles remotely (leveraging on proprietary AI image editing capabilities) and to digitally manage documents, based on blockchain technology.
Stampyt’s innovative and scalable technology supports the digitalisation of the overall customer journey for dealerships and OEMs and is complementary to Imaweb’s existing suite of digital software solutions. We believe that Imaweb’s pan-European presence will support the accelerated roll-out of Stampyt’s technology across the continent, building on its existing position as a market leader in the French used car market. Following the transaction, CEO Alexandre Launay will continue to lead the business alongside Stampyt’s other Co-Founders, executing on the company’s mission to digitalise the automotive industry.
“We are delighted to welcome the Stampyt team as part of Imaweb today,“ said Patrick Prajs, CEO, and Julian Ciccale, Co-Founder and Deputy CEO, at Imaweb. “Stampyt’s technology is innovative and additive to our existing automotive software solutions. We believe that our continental scale combined with Stampyt’s product offering will accelerate the digitalisation of the entire customer journey for dealerships and OEMs across Europe.”
Alexandre Launay, CEO and Co-Founder of Stampyt added, “We’ve been looking for the right partner to help accelerate our growth internationally and our shared vision meant Imaweb was the natural choice. We are excited to work with the teams at both Imaweb and PSG as we lead the group’s innovation strategy going forward.”
PSG invested in Imaweb in May 2019, backing the company’s founders to seek to transform the leading automotive CRM solutions provider in Spain into a pan-European player. Since then, Imaweb has grown quickly through a combination of organic growth and strategic M&A, most recently the acquisition of Procar in Germany in January 2021. Today, Imaweb offers a full suite of digital software solutions to dealerships and OEMs across Europe.
Financial terms were not disclosed.
Notes to Editors
Imaweb
Imaweb is a leading developer and distributor of digital solutions for the automotive sector in Europe. The company was formed through the merger of Imaweb, a Spanish company dedicated to developing global customer management solutions for sales, marketing and after-sales, and DATAFIRST-I’Car Systems group, a French software development company for car manufacturers, group distributors and dealers, in 2019. For more information, visit https://www.imaweb.com/ .
Stampyt
Stampyt is a leading developer and provider of technologies and solutions for the automotive industry. Ease of use and automation are the DNA of the tools developed by Stampyt to digitalise the automotive sector. Stampyt now collaborates with some of the world’s largest OEMs as well as many French automotive groups to provide imaging technology for the automotive industry. https://en.stamp.yt
PSG
PSG is a growth equity firm that partners with middle-market software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 65 companies and facilitated over 275 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams. Founded in 2014, PSG operates out of offices in Boston, Kansas City and London*. https://www.psgequity.com/
*Currently, the London team operates via an advisory agreement with Providence Equity LLP.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom